Literature DB >> 25715965

Bronchiectasis.

Cecile Magis-Escurra1, Monique He Reijers.   

Abstract

INTRODUCTION: Bronchiectasis is usually a complication of previous lower respiratory infection and/or inflammation. It causes chronic cough, copious production of sputum (often purulent), and recurrent infections, and may cause airway obstruction bearing some similarities with that seen in COPD. It may complicate respiratory conditions such as asthma or COPD. It can be associated with primary ciliary dyskinesia, primary immunodeficiencies, certain systemic diseases such as inflammatory bowel disease and rheumatoid arthritis, and foreign body inhalation. Bronchiectasis can be due to cystic fibrosis but this is excluded from this review. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments in people with non-cystic fibrosis (non-CF) bronchiectasis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to January 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). We performed a GRADE evaluation of the quality of evidence for interventions.
RESULTS: We found 23 studies that met our inclusion criteria.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: airway clearance techniques, corticosteroids (inhaled), exercise or physical training, hyperosmolar agents (inhaled), mucolytics, prolonged-use antibiotics, and surgery.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25715965      PMCID: PMC4356176     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  32 in total

1.  Risk factors affecting outcome and morbidity in the surgical management of bronchiectasis.

Authors:  Sevval Eren; Hidir Esme; Alper Avci
Journal:  J Thorac Cardiovasc Surg       Date:  2007-08       Impact factor: 5.209

2.  Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score.

Authors:  Miguel Á Martínez-García; Javier de Gracia; Monserrat Vendrell Relat; Rosa-Maria Girón; Luis Máiz Carro; David de la Rosa Carrillo; Casilda Olveira
Journal:  Eur Respir J       Date:  2013-11-14       Impact factor: 16.671

3.  Surgical management of bronchiectasis: the indications and outcomes.

Authors:  Soner Gursoy; Ali Ata Ozturk; Ahmet Ucvet; Ahmet Emin Erbaycu
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

4.  A Delphi study of pharmacotherapy for noncystic fibrosis bronchiectasis.

Authors:  Marc A Judson; Haroon Chaudhry; Damian R Compa; Anne E OʼDonnell
Journal:  Am J Med Sci       Date:  2014-11       Impact factor: 2.378

5.  Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.

Authors:  A E O'Donnell; A F Barker; J S Ilowite; R B Fick
Journal:  Chest       Date:  1998-05       Impact factor: 9.410

6.  Treatment With tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa.

Authors:  L A Couch
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

7.  Bronchiectasis: an orphan disease with a poorly-understood prognosis.

Authors:  T Keistinen; O Säynäjäkangas; T Tuuponen; S L Kivelä
Journal:  Eur Respir J       Date:  1997-12       Impact factor: 16.671

8.  Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.

Authors:  Diana Bilton; Evangelia Daviskas; Sandra D Anderson; John Kolbe; Gregory King; Rob G Stirling; Bruce R Thompson; David Milne; Brett Charlton
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

9.  Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.

Authors:  Patricia C Valery; Peter S Morris; Catherine A Byrnes; Keith Grimwood; Paul J Torzillo; Paul A Bauert; I Brent Masters; Abbey Diaz; Gabrielle B McCallum; Charmaine Mobberley; Irene Tjhung; Kim M Hare; Robert S Ware; Anne B Chang
Journal:  Lancet Respir Med       Date:  2013-09-17       Impact factor: 30.700

10.  Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.

Authors:  David J Serisier; Diana Bilton; Anthony De Soyza; Philip J Thompson; John Kolbe; Hugh W Greville; David Cipolla; Paul Bruinenberg; Igor Gonda
Journal:  Thorax       Date:  2013-05-16       Impact factor: 9.139

View more
  3 in total

Review 1.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

2.  Factors associated with bronchiectasis in Korea: a national database study.

Authors:  Bumhee Yang; Hyo Jun Jang; Sung Jun Chung; Seung-Jin Yoo; Taehee Kim; Sun-Hyung Kim; Yoon Mi Shin; Hyung Koo Kang; Jung Soo Kim; Hayoung Choi; Hyun Lee
Journal:  Ann Transl Med       Date:  2020-11

3.  Risk factors for bronchiectasis in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  XinXin Zhang; LiJian Pang; XiaoDong Lv; HaoYang Zhang
Journal:  Clinics (Sao Paulo)       Date:  2021-04-16       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.